King, Allen B. Diabetes Care Center
Kuroda, Akio Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Matsuhisa, Munehide Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Hobbs, Todd Novo Nordisk
Type 1 diabetes
Continuous subcutaneous insulin infusion
Dosing guidelines for patients with type 1 diabetes using continuous subcutaneous insulin infusion (CSII), which are historically based on clinical experience and retrospective studies of patients consuming an American diet, recommend that basal insulin should represent approximately 50 % of the total daily dose (TDD). Recent prospective studies in the USA and Japan conclude that the more appropriate proportion is closer to 30–40 % of TDD. In addition, currently used formulas for calculating the carbohydrate-to-insulin ratio (CIR) and correction factor (CF) may lead to underdosing of bolus insulin by as much as 12.8–50 % for a hypothetical patient. The discrepancies between traditional formulas and data from newer studies can be accounted for by the more rigorous design of the newer studies (e.g., prospective design, controlled diets, meal omission, and frequent glucose monitoring). International differences in diet composition may also be important to consider when developing dosing recommendations for CSII.
Current Diabetes Reports
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
|DOI (Published Version)|
|URL ( Publisher's Version )|
cdr_16_9_83.pdf 334 KB
Institute of Advanced Medical Sciences